Patrick J. O'Malley

Patrick J. O'Malley

Partner

Seattle
About

Patrick O'Malley is a partner in the Seattle office focusing his practice on representing issuers and investment banks in capital markets transactions.  Patrick regularly advises clients listed on the NASDAQ Stock Market, NYSE and NYSE American, as well as international exchanges. Patrick principally represents established and emerging life sciences, biotech, medical device, and technology companies, providing guidance on a range of matters, including corporate governance, SEC periodic and current reporting, proxy statements, and related corporate and disclosure advice.

Patrick also represents both selling companies and acquirers in merger and acquisition transactions, primarily representing public clients and private clients merging into public shell companies. Patrick has advised numerous private companies in venture capital financing and corporate governance and Board of Director matters. 

Areas of FocusCorporateEmerging Growth and Venture CapitalEquity Capital MarketsCapital Markets and Public Company Advisory
Bar admissionsCaliforniaWashington

EXPERIENCE

Representative Matters
  • Zeltiq Aesthetics (Nasdaq: ZLTQ) in its US$105 million initial public offering
  • Neothetics in its US$65 million initial public offering and its sale to Evofem Biosciences
  • Nexvet Biopharma (Nasdaq: NVET) in its US$40 million initial public offering
  • Sientra in its US$115 million follow‑on offering
  • Halozyme Therapeutics, Inc. in numerous follow‑on offerings
  • GenMark Diagnostics (Nasdaq: GNMK) in its initial public offering and numerous follow‑on offerings
  • Maxwell Technologies in its follow‑on offering and convertible note offering
  • DragonWave (Nasdaq: DRWI; TSX: DRI) in numerous follow‑on offerings
  • Cytori Therapeutics (Nasdaq: CYTX) in numerous follow‑on offerings and rights offering
  • Mast Therapeutics, Inc. in its sale to Savara and in numerous follow‑on offerings
  • QUALCOMM Incorporated in numerous acquisitions, venture financings and other strategic transactions
  • DTS in its US$1.0 billion sale to Tessera Technologies, as well as numerous acquisitions
  • NuVasive in its US$650 million 2.25% Convertible Senior Note offering and numerous acquisitions
  • P.F. Chang's China Bistro in its US$1.1 billion sale to Centerbridge Partners
  • The Active Network, Inc. in its US$1.05 billion sale to Vista Equity Partners
  • Life Technologies Corporation in various acquisitions, venture financings and other strategic transactions
  • Reva Medical (ASX: RVA) in its convertible note offerings
  • aTyr Pharma Inc. in its venture financings and other strategic transactions
  • Epic Sciences, Inc. in its venture financings and other strategic transactions

Awards

The Legal 500 United States

  • Recommended, Capital Markets: Equity Offerings (2024)
  • Recommended, Capital Markets Equity Offerings – Advice to Issuers (2024)
  • Recommended, Capital Markets Equity Offerings – Advice to Managers (2023-2024)
Education
  • J.D., Georgetown University Law Center 2010
    Member, The Tax Lawyer
  • B.A., University of Notre Dame 2007

Prior Experience

  • Judicial Extern to Honorable Marilyn Huff, Southern District of California

My latest insights

News

DLA Piper advises Bacardi in US$1 billion notes offering

4 February 2025 .1 minute read

News

DLA Piper advises Akoya Biosciences in its business combination with Quanterix

13 January 2025 .1 minute read

News

DLA Piper advises Palomar Holdings, Inc. in pricing of public offering of common stock

26 August 2024 .1 minute read

View All
CallvCardLinkedInPrint

Connect

Phone

+1 206 839 4831
(Work, Seattle)